INFLAmmasomes NLRP3 in Platelets and Leukocytes During SEPSIS in Intensive Care Unit

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

11 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-27

Study Completion Date

2023-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

septic shock is the first cause of mortality in intensive care unit. Innate immunity is the body's first line of defense against pathogens

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 : Study of INFLAmmasome and PLAtelets Functions

NCT04397822

COVID-19

COMPLETED

Study of Platelet Activation in Septic Shock Patients

NCT02635854

Septic Shock

COMPLETED NA

Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.

NCT04080453

Septic Shock

COMPLETED

Platelet-associated Inflammation in Severe Sepsis

NCT03029039

Severe Sepsis

COMPLETED

Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis

NCT06657781

Bacterial Sepsis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

since their discovery, inflammasomes have an important role during inflammatory response following an aggression. There are intracytoplasmic multiprotein complex activated by cellular stress or infections and is responsible for the release of pro-inflammatory cytokines, including IL-1β. One study focused on the role of the NLRP3 inflammasome in monocyte during sepsis has shown its early alteration that is correlated with mortality. Most studies have analysed inflammasomes in nucleated cells, nevertheless, little is known about inflammasomes in platelets. The aim of the study is to analyze the activation of NLRP3 inflammasome in platelets and leukocytes during sepsis, from patients hospitalized in intensive care unit compare to a control group, until its resolution to better understand the pathophysiology of sepsis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis group

patients suffering from sepsis hospitalized in intensive care unit

Blood collection

Intervention Type OTHER

Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes

Control group

patients without infection hospitalized in intensive care unit

Blood collection

Intervention Type OTHER

Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood collection

Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hospitalized in intensive care unit with central catheter
* age \> or = 18 years
* patients suffering from sepsis
* hospitalized from less than72 hours

* hospitalized in intensive care unit with central catheter for other reason than infection
* age \> or = 18 years

Exclusion Criteria

* patients with curatorship or guardianship
* pregnant women
* patients suffering from malignant blood disease
* patients suffering from disease associated with NLRP3 inflammasome activation

CONTROL GROUP:

* patients with infection disease
* patients with curatorship or guardianship
* pregnant women
* patients suffering from malignant blood disease
* patients suffering from disease associated with NLRP3 inflammasome activation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No